Build status - In Progress

NONINTERVENTIONAL EXTENSION STUDY FOR PATIENTS TREATED IN STUDY R5459-RT-1944 WITH REGN5459 OR REGN5458 (BCMA CD3 BISPECIFIC ANTIBODIES) WHO RECEIVE A KIDNEY TRANSPLANT

Recruiting
99 years or below
All
Phase N/A
3 participants needed
1 Location

Brief description of study

The primary objective of the study is to assess adverse events (AEs) and serious adverse events (SAEs) in kidney transplant recipients previously treated with REGN5459 or REGN5458 in the R5459-RT-1944 study. The primary endpoint for this study is the incidence of AEs and SAEs over a 12-month period, starting at the time of kidney transplantation.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

  •  Kidney transplant recipient enrolled in research study R5459-RT-1944 and received investigational product treatment. 

Updated on 04 Aug 2024. Study ID: 851581

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center